Dermatology CPT Code Framework
Dermatology billing is procedure dense, which means one office visit can generate several valid CPT lines or several preventable denials. A typical encounter may include an established patient E/M visit, a tangential biopsy, destruction of actinic keratoses, and a pathology specimen sent to the lab. Mohs surgery, repairs, excisions, and biologic injections add another layer of coding complexity because each procedure family has its own unit logic, modifier rules, and documentation standards. The specialty depends on matching lesion type, lesion count, anatomic site, and pathology results to the exact procedure code.
That precision matters because dermatology payers scrutinize medical necessity, especially when the same clinic performs both medical and cosmetic services. If the chart describes benign cosmetic removal but the claim bills a medically necessary destruction code, the payer denies or audits the service. If the physician removes ten actinic keratoses but the claim bills only one lesion, the practice leaves revenue behind. Clean dermatology coding is less about memorizing a few codes and more about aligning the operative note with the payer’s decision logic.
Biopsy Codes 11102 Through 11107
Dermatology biopsy coding starts with the technique. CPT code 11102 covers the first tangential biopsy and often reimburses about $95 to $135. CPT code 11104 covers the first punch biopsy and generally falls around $110 to $150. CPT code 11106 covers the first incisional biopsy and typically reimburses about $120 to $165. Additional lesions of the same technique use add-on codes 11103, 11105, and 11107. The note should clearly identify the technique, lesion location, and the number of distinct specimens taken. If the physician performs one tangential biopsy and one punch biopsy on the same day, each first-lesion code may be appropriate because the biopsy techniques differ.
Biopsy claims become vulnerable when the documentation does not separate lesions clearly. A note that says “two biopsies taken” without naming the lesion sites or biopsy methods leaves too much ambiguity for coding and audit defense. Pathology coordination is also important because the professional pathology interpretation is billed separately by the lab or pathology provider, not bundled into the skin biopsy procedure code.
Destruction Codes for Premalignant and Benign Lesions
CPT code 17000 covers destruction of the first premalignant lesion such as an actinic keratosis and commonly reimburses about $70 to $95. CPT code 17003 is billed for each additional premalignant lesion after the first, and CPT code 17004 applies when fifteen or more premalignant lesions are destroyed during the session. Benign lesion destruction uses a different code family. CPT code 17110 generally covers destruction of one to fourteen benign lesions and may reimburse around $90 to $125, while CPT code 17111 covers fifteen or more benign lesions and often lands near $135 to $185.
The billing risk is straightforward: premalignant lesion counts and benign lesion counts cannot be mixed casually. If the physician destroys twelve actinic keratoses, the coding logic is 17000 plus eleven units of 17003, not 17110. If the lesions are benign seborrheic keratoses, 17110 or 17111 may apply instead. The pathology or clinical diagnosis in the note has to support the lesion family used on the claim.
Excision and Repair Codes
Excision codes in dermatology depend on lesion behavior, location, and the excised diameter including margins. Benign lesion excisions fall in the 11400 through 11446 series. Malignant lesion excisions use 11600 through 11646. A small benign lesion on the trunk may reimburse around $120 to $170, while a larger malignant excision on the face with more complex closure can move much higher. Closure coding matters too. Simple closure is usually included in the excision, but intermediate or complex repair may be billed separately when documentation supports layered closure or extensive undermining.
Dermatology practices lose revenue when the operative note gives only the lesion size and omits the excised diameter with margins. They also create compliance risk when the diagnosis stays benign after pathology confirms malignancy, or when the claim bills malignant excision codes before the record supports that classification. The billing team should reconcile pathology findings and procedure coding promptly when final pathology changes the diagnosis.
Mohs Surgery and Staged Procedures
Mohs micrographic surgery has its own code set. CPT code 17311 covers the first stage on the head, neck, hands, feet, genitalia, or any location where tissue-sparing work is especially significant. CPT code 17312 covers each additional stage on those same anatomic areas. CPT codes 17313 and 17314 apply to trunk, arms, and legs. Tissue block counts and repair services must be documented carefully because Mohs billing is stage based, not simply time based. Reimbursement often ranges from the mid hundreds into four figures depending on stages, blocks, repair complexity, and site.
Mohs coding fails when the operative note does not separate stages and tissue blocks clearly or when the repair documentation is too vague to support the closure billed after the Mohs work. Dermatology groups also need to distinguish Mohs from standard excision so the claim logic, pathology workflow, and global-period expectations stay clean.
Drug Administration and Phototherapy Codes
Dermatology practices using biologics, intralesional injections, and phototherapy need clean ancillary coding. CPT code 11900 covers intralesional injection of up to seven lesions and often reimburses about $65 to $95. CPT code 11901 covers more than seven lesions. Photochemotherapy and phototherapy codes in the 96900 through 96913 range vary based on modality and supervision. Drug supply billing may require J-codes for biologic agents when the practice bills buy-and-bill medications under the medical benefit.
These services depend on exact documentation of the lesion count, drug used, dose administered, route, and payer authorization status. Many biologics are carved out to specialty pharmacy pathways, so the billing team should confirm whether the drug is being supplied by the office or by an outside pharmacy before building the claim.
How MMBS Supports Dermatology Coding Accuracy
MMBS maintains a 98.2% clean claim rate across specialties by matching dermatology procedure coding to lesion type, anatomic site, pathology workflow, and payer-specific modifier logic before the claim reaches the clearinghouse. For dermatology groups, that means reviewing biopsy method selection, lesion counts, staged Mohs documentation, and cosmetic-versus-medical classification so reimbursement is protected without pushing the practice into avoidable audit risk.